CA2276149A1 - Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque - Google Patents

Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque Download PDF

Info

Publication number
CA2276149A1
CA2276149A1 CA002276149A CA2276149A CA2276149A1 CA 2276149 A1 CA2276149 A1 CA 2276149A1 CA 002276149 A CA002276149 A CA 002276149A CA 2276149 A CA2276149 A CA 2276149A CA 2276149 A1 CA2276149 A1 CA 2276149A1
Authority
CA
Canada
Prior art keywords
igf
patient
amount
serum
insulin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002276149A
Other languages
English (en)
Inventor
Fred I. Chasalow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2276149A1 publication Critical patent/CA2276149A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La présente invention concerne des compositions et des méthodes destinées au traitement de l'insulinorésistance et à l'amélioration de conditions pathologiques liées à celle-ci. L'invention concerne également des procédés d'identification de patients susceptibles de développer un diabète sucré non insulinodépendant ou une insulinorésistance. L'invention concerne, en outre, des procédés d'identification de patients susceptibles de développer une hypoglycémie réactive ou d'en souffrir, et des méthodes de traitement de ceux-ci.
CA002276149A 1996-12-24 1997-12-23 Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque Abandoned CA2276149A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3450496P 1996-12-24 1996-12-24
US3741797P 1997-02-21 1997-02-21
US60/034,504 1997-02-21
US60/037,417 1997-02-21
PCT/US1997/023481 WO1998027813A1 (fr) 1996-12-24 1997-12-23 Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque

Publications (1)

Publication Number Publication Date
CA2276149A1 true CA2276149A1 (fr) 1998-07-02

Family

ID=26711037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002276149A Abandoned CA2276149A1 (fr) 1996-12-24 1997-12-23 Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque

Country Status (5)

Country Link
EP (1) EP1009232A4 (fr)
JP (1) JP2001508770A (fr)
AU (1) AU5709698A (fr)
CA (1) CA2276149A1 (fr)
WO (1) WO1998027813A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2212245C1 (ru) * 2002-03-04 2003-09-20 Нуртдинов Марат Акдасович Способ хирургического лечения сахарного диабета
KR20230090336A (ko) 2020-10-13 2023-06-21 베타바이브 리미티드 당뇨병 및 관련된 대사성 질환을 치료하기 위한 방법 및 화합물
MX2024004398A (es) 2021-10-12 2024-07-09 Betavive Ltd Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
WO1998027813A1 (fr) 1998-07-02
EP1009232A1 (fr) 2000-06-21
EP1009232A4 (fr) 2002-06-12
JP2001508770A (ja) 2001-07-03
AU5709698A (en) 1998-07-17

Similar Documents

Publication Publication Date Title
BOWSHER et al. Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids
KR100367943B1 (ko) 클로닝된 글루탐산 디카르복실라아제
Cummins et al. Cardiac specific troponin-I release in canine experimental myocardial infarction: development of a sensitive enzyme-linked immunoassay
US5137873A (en) Substance p and tachykinin agonists for treatment of alzheimer's disease
US7815905B2 (en) Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
US5866547A (en) Methods of neuroendocrine regulation of affective disorders
EP0260306A4 (en) Method of assay of inhibin
Stein et al. Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia
EP3515928B1 (fr) Polypeptides non répétitifs non structurés ayant un comportement lcst
Eysselein et al. Biological activity of canine intestinal cholecystokinin-58
SEINO et al. Characterization of circulating insulin in insulin autoimmune syndrome
CA2276149A1 (fr) Methodes de traitement de l'insulinoresistance et procedes d'identification de patients presentant ce risque
US5919902A (en) Leptin bound to inter-alphatrypsin inhibitor and uses thereof
US20020165127A1 (en) Methods for treating insulin resistance and identifying patients at risk for the disease
Ensinck et al. Studies of Insulin Antagonism: I. An Artifactual Antagonist to Insulin and Plasma Nonsuppressible Insulin-like Activity Occurring in Preparation of “Albumin”
Maringhini et al. Is the plasma amino acid consumption test an accurate test of exocrine pancreatic insufficiency?
Gong et al. The effects of obesity on bone turnover markers in diabetic patients with diabetic ketosis or ketoacidosis
Klein et al. High performance liquid chromatography used to distinguish the autoimmune hypoglycemia syndrome from factitious hypoglycemia
Retegui et al. Specificities of antibodies to human growth hormone (hGH) in patients treated with hGH: longitudinal study and comparison with the specificities of animal antisera
US20100292147A1 (en) Identification of the hepcidin binding site on ferroportin
Madsen et al. Plasma immunoreactive neuropeptide Y in congestive heart failure at rest and during exercise
Carlsson et al. Assay systems for the growth hormone-binding protein
WO1993009798A1 (fr) Methodes therapeutiques et diagnostiques basees sur l'expression de nt-3 specifique de tissus et sur la liaison de recepteurs
Beinfeld Peptides in rat brain immunoreactive for the carboxyl terminal extension of cholecystokinin: distribution and chromatography
Tanaka et al. Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris

Legal Events

Date Code Title Description
FZDE Dead